We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nevro's (NVRO) FDA Submission to Treat Patients With PDN
Read MoreHide Full Article
Nevro Corp. (NVRO - Free Report) recently announced that it has submitted a pre-market approval supplement to the FDA to get authorization for its Senza System. The approval is required for the treatment of chronic pain related to Painful Diabetic Neuropathy (PDN).
It is worth mentioning that about one in 10 adults in the United States suffer from diabetes, which can damage peripheral nerves leading to severe pain and numbness in the extremities. In fact, per published literature, around 4 million diabetic patients are suffering from PDN in the United States alone.
Following this announcement, Senza — Nevro’s flagship platform and key driver of growth — is likely to receive a boost. Notably, Senza has been developed and commercialized for the treatment of chronic pain. The system delivers paresthesia-free HF10 therapy, a superior one over traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain.
More on the News
Notably, Nevro’s SENZA-PDN study is the largest randomized clinical trial (RCT) of spinal cord stimulation treatment that has been conducted to date. The study draws comparison with the HF10 therapy plus Conventional Medical Management (CMM) to CMM alone in 216 patients across 18 centers in the United States.
The RCT has been developed to offer safety and effective data that can be utilized to lend support to customer adoption and efforts to enable required payor coverage of this procedure.
The submission marks a key milestone in the evaluation of HF10 high frequency spinal cord stimulation therapy that can provide relief with presently available pharmacologic options to many PDN patients.
Post review and regulatory approval of the submission, the company can commence U.S. launch activities for the Senza System and HF10 therapy for treating chronic pain in PDN patients in the second half of 2021.
Market Prospects
Per a report by Fortune Business Insights, the global diabetic neuropathy market size was worth $3.61 billion in 2018 and is expected to reach $7.12 billion by 2026, witnessing a CAGR of 8.9% during the forecast period (2019-2026). Hence, the announcement is a well-timed one for Nevro.
Notable Developments
In June 2020, Nevro announced that it has received TGA approval and Jul 1, 2020 Prostheses Listing for the Senza Omnia Spinal Cord Stimulation (SCS) system — a next generation system developed to help physicians manage chronic pain with maximum versatility.
In May, the company announced that it has received CE mark approval for the SCS system, which is likely to aid Nevro in strengthening its already solid international presence.
Price Performance
Shares of this Zacks Rank #3 (Hold) stock gained 52.4% in a year’s time, outperforming the industry’s growth of 18.8%.
Merit Medical has a projected long-term earnings growth rate of 12.6%.
Patterson Companies has an estimated long-term earnings growth rate of 9.6%.
McKesson has a projected long-term earnings growth rate of 6.6%.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
Image: Bigstock
Nevro's (NVRO) FDA Submission to Treat Patients With PDN
Nevro Corp. (NVRO - Free Report) recently announced that it has submitted a pre-market approval supplement to the FDA to get authorization for its Senza System. The approval is required for the treatment of chronic pain related to Painful Diabetic Neuropathy (PDN).
It is worth mentioning that about one in 10 adults in the United States suffer from diabetes, which can damage peripheral nerves leading to severe pain and numbness in the extremities. In fact, per published literature, around 4 million diabetic patients are suffering from PDN in the United States alone.
Following this announcement, Senza — Nevro’s flagship platform and key driver of growth — is likely to receive a boost. Notably, Senza has been developed and commercialized for the treatment of chronic pain. The system delivers paresthesia-free HF10 therapy, a superior one over traditional low-frequency spinal cord stimulation for the treatment of chronic back and leg pain.
More on the News
Notably, Nevro’s SENZA-PDN study is the largest randomized clinical trial (RCT) of spinal cord stimulation treatment that has been conducted to date. The study draws comparison with the HF10 therapy plus Conventional Medical Management (CMM) to CMM alone in 216 patients across 18 centers in the United States.
The RCT has been developed to offer safety and effective data that can be utilized to lend support to customer adoption and efforts to enable required payor coverage of this procedure.
The submission marks a key milestone in the evaluation of HF10 high frequency spinal cord stimulation therapy that can provide relief with presently available pharmacologic options to many PDN patients.
Post review and regulatory approval of the submission, the company can commence U.S. launch activities for the Senza System and HF10 therapy for treating chronic pain in PDN patients in the second half of 2021.
Market Prospects
Per a report by Fortune Business Insights, the global diabetic neuropathy market size was worth $3.61 billion in 2018 and is expected to reach $7.12 billion by 2026, witnessing a CAGR of 8.9% during the forecast period (2019-2026). Hence, the announcement is a well-timed one for Nevro.
Notable Developments
In June 2020, Nevro announced that it has received TGA approval and Jul 1, 2020 Prostheses Listing for the Senza Omnia Spinal Cord Stimulation (SCS) system — a next generation system developed to help physicians manage chronic pain with maximum versatility.
In May, the company announced that it has received CE mark approval for the SCS system, which is likely to aid Nevro in strengthening its already solid international presence.
Price Performance
Shares of this Zacks Rank #3 (Hold) stock gained 52.4% in a year’s time, outperforming the industry’s growth of 18.8%.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Merit Medical Systems, Inc. (MMSI - Free Report) , Patterson Companies, Inc. (PDCO - Free Report) and McKesson Corporation (MCK - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Merit Medical has a projected long-term earnings growth rate of 12.6%.
Patterson Companies has an estimated long-term earnings growth rate of 9.6%.
McKesson has a projected long-term earnings growth rate of 6.6%.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.4% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>